P15
from the University of Richmond, Virginia and he also holds a Ph.D. in Pharmacology & Toxicology from the Medical College of Virginia, at Virginia Commonwealth University. Subsequent to the year end, on 4 January 2010 he resigned as a Director and Chief Executive Officer.
• Keith Bigsby (Chief Financial Officer) was appointed on 27 April 2007. After qualifying as a Chartered Accountant, Mr. Bigsby has had over 30 years of senior financial management and board room experience in the technology sector. He has held senior finance positions across Europe, the USA and the Far East, a significant proportion of which has been as Chief Financial Officer (including for publicly listed companies) most recently at Geotrupes Energy Plc and Tadpole Technology Plc. Prior to this he was for six years the European Regional CFO for Wang and held Regional Finance Director roles in the UK and France for Sun Microsystems. He has a significant background in complex business environments, strategic planning and process re-engineering.
• Alan Reade (Executive Chairman) was appointed on
25 May 2007 as Non-executive Director. He is owner of Global Strategy Expression Limited, a consulting and advisory services business in the life sciences industry. From 2000 until his retirement in 2005, he served as executive chairman of Merial Limited, a leading animal health company and joint venture between Merck & Co. Inc. and Sanofi-Aventis. Earlier in his career he was head of global integration at Aventis, where he was in charge of merger integration, and Chief Executive Officer and member of the Global Executive Committee at Rhone-Poulenc Inc. He previously has been a director of Sygen International and IFAH, a global animal health association. He was chairman of the Remuneration Committee and a member of the Nomination Committee throughout the year. Subsequent to the year end, on 4 January 2010 he was appointed as Executive Chairman.
• Barry Riley (Non-executive Director) was appointed
on 25 May 2007. After qualifying as a Chartered Accountant, he joined the Bowater Organization, where he had responsibility for the finance function at several operations. From there he moved to FMC Corporation, the U.S. conglomerate where he had finance and general management responsibilities for a specialty chemical operation, and also oversaw the head office finance function for all UK operations. He joined Proteus International plc in 1995 as Finance Director and was closely involved in the merger with Therapeutic
Antibodies Inc. in 1999, which became Protherics Plc where he was Finance Director until 2007. He is chairman
of the Audit Committee and a member of the Nomination Committee.
• Ken Noonan (Senior Independent Non-executive Director) was appointed on 25 May 2007. He was a Partner at LEK Consulting LLP based in London, where he led the firm's life sciences practice in the UK and Europe, with responsibility for pharmaceuticals, biotechnology and in
vitro diagnostics until he retired in 2008. He is currently a technology partner at Advanced Technology Partners. Other positions held by Dr. Noonan included Senior Vice President of Corporate Development for Applera Corporation and
Vice President at Booz-Allen & Hamilton and head of its European Pharmaceutical Practice. He currently serves on the Board of Orchid Biosciences Inc. and Intercept Pharmaceuticals Inc. During his academic career he authored over 50 articles in cancer biology/cell replication and holds a B.S. from St. Josephs University and a Ph.D. in Biochemistry from Princeton University. He is a member of the Audit Committee and of the Remuneration Committee and from 4 January 2010 he has been Chairman of the Remuneration Committee.
• David Szostak (Non-executive Director) was appointed on 4 April 2008. He is Chief Financial Officer of XL TechGroup Inc. and PetroAlgae LLC, as well as President of PetroAlgae Inc. He has over 20 years experience in industry. Other positions held by Mr. Szostak were CFO of Hetra Computer Inc. and Corporate Controller at Extel, Inc. Mr. Szostak has a Bachelor of Science in Finance at Southern Illinois University, with graduate studies at DePaul University in Chicago. David resigned on 16 September 2009.
• Patrick Regan (Non-executive Director) was appointed on 16 September 2009. He brings to the Board over sixteen years of financial analysis, corporate management, investment banking and venture capital experience gained in the US. Mr. Regan has been a senior managing director for Laurus Capital Management LLC since 2001 and has also served the same role at Valens Capital Management LLC since its establishment in 2007. In addition to his fund management experience at Laurus/Valens, he has spent four years as a financial analyst at Geller & Company. At Geller, he was involved in private placement financing, management consulting and general corporate finance functions. Between 1999 and 2001, Patrick Regan was an associate at Tower Hill Capital Group, an investment banking boutique and venture capital firm.
